On February 5, 2019, Mundipharma announced the European launch of Pelmeg® (pegfilgrastim), a biosimilar of Neulasta®. As we have previously reported, Mundipharma acquired Pelmeg® from Cinfa Biotech and it was approved by the European Commission in November 2018. According to the press release, Pelmeg® is now available in Germany, the Netherlands, and Ireland, and the fourth biosimilar medicine to be commercialized by Mundipharma.